Michelle Kuhne

2.8k total citations · 1 hit paper
35 papers, 2.2k citations indexed

About

Michelle Kuhne is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Michelle Kuhne has authored 35 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Immunology, 17 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in Michelle Kuhne's work include Monoclonal and Polyclonal Antibodies Research (12 papers), Immunotherapy and Immune Responses (10 papers) and CAR-T cell therapy research (8 papers). Michelle Kuhne is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (12 papers), Immunotherapy and Immune Responses (10 papers) and CAR-T cell therapy research (8 papers). Michelle Kuhne collaborates with scholars based in United States, New Zealand and Germany. Michelle Kuhne's co-authors include Arthur Weiss, Gustav E. Lienhard, Deborah Yablonski, Tony Pawson, Theresa A. Kadlecek, Guosheng Feng, Alan J. Korman, Pina M. Cardarelli, Gregory Ku and M. S. Srinivasan and has published in prestigious journals such as Science, Journal of Biological Chemistry and The Journal of Experimental Medicine.

In The Last Decade

Michelle Kuhne

34 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

2014 472 citations Changyu Wang, Kent Thudium et al. Cancer Immunology Research profile →

Peers

Countries citing papers authored by Michelle Kuhne

Since Specialization

Citations

This map shows the geographic impact of Michelle Kuhne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Kuhne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Kuhne more than expected).

Fields of papers citing papers by Michelle Kuhne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Kuhne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Kuhne. The network helps show where Michelle Kuhne may publish in the future.

Co-authorship network of co-authors of Michelle Kuhne

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Kuhne. A scholar is included among the top collaborators of Michelle Kuhne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Kuhne. Michelle Kuhne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors 2024 ·Clinical Cancer Research ·Anthony W. Tolcher, Joshua Brody, Nishanthan Rajakumaraswamy, Michelle Kuhne, Torsten Trowe, Anees M. Dauki, (unknown), (unknown), Kai-Wen Lin, (unknown), Shivaani Kummar	13
2	Pharmacokinetics, pharmacodynamics, and safety of GS‐3583, a FLT3 agonist Fc fusion protein, from single‐ascending‐dose phase I study in healthy participants 2024 ·Clinical and Translational Science ·Anees M. Dauki, Nishanthan Rajakumaraswamy, Torsten Trowe, (unknown), (unknown), (unknown), Ann Qin, Christian Schwabe, Michelle Kuhne, Ahmed A. Othman	1
3	Mapping binding epitopes of monoclonal antibodies targeting major histocompatibility complex class I chain-related A (MICA) with hydrogen/deuterium exchange and electron-transfer dissociation mass spectrometry 2020 ·Analytical and Bioanalytical Chemistry ·Richard Y.‐C. Huang, Michelle Kuhne, Shrikant Deshpande, Vangipuram S. Rangan, M. S. Srinivasan, Yun Wang, Guodong Chen	12
4	In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates breakdown → 2014 ·Cancer Immunology Research ·Changyu Wang, Kent Thudium, Minhua Han, Xitao Wang, Haichun Huang, Diane Feingersh, Candy Garcia, Yi Wu, Michelle Kuhne, M. S. Srinivasan, Sujata Singh, Susan Wong, Neysa Garner, Heidi Leblanc, Roderick T. Bunch, Diann Blanset, Mark Selby, Alan J. Korman	472
5	A Novel Activating Mutation Of CXCR4 Plays a Crucial Role In Waldenstrom Macroglobulinemia Biology 2013 ·Blood ·Aldo M. Roccaro, Antonio Sacco, Cristina Jiménez, Patricia Maiso, Michele Moschetta, Yuji Mishima, Michelle Kuhne, Pina M. Cardarelli, (unknown), Ramón García‐Sánz, Irene M. Ghobrial	4
6	BMS-936564 (Anti-CXCR4 Antibody) Induces Specific Leukemia Cell Mobilization and Objective Clinical Responses In CLL Patients Treated Under a Phase I Clinical Trial 2013 ·Blood ·Manoj Kumar Kashyap, (unknown), (unknown), (unknown), Michael Y. Choi, Michelle Kuhne, Lewis Cohen, Peter Sabbatini, Thomas J. Kipps, Pina M. Cardarelli, Januario E. Castro	6
7	BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies 2012 ·Clinical Cancer Research ·Michelle Kuhne, (unknown), (unknown), (unknown), Chin Pan, (unknown), Fei Cao, (unknown), (unknown), Karla A. Henning, Lewis Cohen, Alan J. Korman, Pina M. Cardarelli	181
8	CXCR4 Monoclonal Antibody, BMS-936564 (MDX-1338), Modulates Epithelial to Mesenchymal Transition (EMT) in Multiple Myeloma Cells 2012 ·Blood ·Aldo M. Roccaro, Antonio Sacco, Michelle Kuhne, Abdel Kareem Azab, Patricia Maiso, Feda Azab, Salomon Manier, (unknown), Michaela R. Reagan, Lewis Cohen, Pina M. Cardarelli, Irene M. Ghobrial	1
9	Abstract #LB-150: A fully human anti-CXCR4 antibody induces apoptosis in vitro and shows anti tumor activity in vivo. 2009 ·Cancer Research ·Michelle Kuhne, (unknown), (unknown), (unknown), Chin Pan, (unknown), (unknown), (unknown), (unknown), Karla A. Henning, Lewis Cohen, Diann Blanset, Alan J. Korman, Pina M. Cardarelli	1
10	A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies 2009 ·Cancer Immunology Immunotherapy ·Pina M. Cardarelli, (unknown), (unknown), Haichun Huang, (unknown), (unknown), Chin Pan, (unknown), David Passmore, Jie Liu, Michelle Kuhne, (unknown), Diann Blanset, David J. King	39
11	W1170 CXCL10 Expression and Biological Activities in Inflammatory Bowel Disease 2008 ·Gastroenterology ·(unknown), Michelle Kuhne, (unknown), (unknown), (unknown), (unknown), Michael Yellin, Kiron M. Das, Pina M. Cardarelli	2
12	Characterization of MDX-1401, a Human Anti-CD30 Antibody with Enhanced Effector Function, for Therapy of Malignant Lymphoma. 2008 ·Blood ·Pina M. Cardarelli, (unknown), (unknown), Amelia Black, David Passmore, Tseng-hui Timothy Chen, (unknown), Jie Liu, Michelle Kuhne, M. S. Srinivasan, Albert Assad, (unknown), Marco Coccia, Robert F. Graziano, David J. King	1
13	MDX-1100, a fully human anti-CXCL10 (IP-10) antibody, is a high affinity, neutralizing antibody that has entered Phase I clinical trials for the treatment of Ulcerative Colitis (UC). (131.20) 2007 ·The Journal of Immunology ·Michelle Kuhne, Benjamin L. Preston, Steven P. Wallace, (unknown), (unknown), (unknown), Pina M. Cardarelli	6
14	Linker for Activation of T Cells, ζ-Associated Protein-70, and Src Homology 2 Domain-Containing Leukocyte Protein-76 are Required for TCR-Induced Microtubule-Organizing Center Polarization 2003 ·The Journal of Immunology ·Michelle Kuhne, Joseph Lin, Deborah Yablonski, Marianne Mollenauer, Lauren I. R. Ehrlich, Johannes B. Huppa, Mark M. Davis, Arthur Weiss	92
15	A Guanine Nucleotide Exchange Factor-independent Function of Vav1 in Transcriptional Activation 2000 ·Journal of Biological Chemistry ·Michelle Kuhne, Gregory Ku, Arthur Weiss	94
16	Evidence Against Dephosphorylation of Insulin-Elicited Phosphotyrosine Proteins in Vivo by the Phosphatase PTP2C 1995 ·Biochemical and Biophysical Research Communications ·Michelle Kuhne, Zhihe Zhao, Gustav E. Lienhard	12
17	Dephosphorylation of insulin receptor substrate 1 by the tyrosine phosphatase PTP2C. 1994 ·Journal of Biological Chemistry ·Michelle Kuhne, Z Zhao, (unknown), Brian E. Lavan, Shiyang Shen, Edmond H. Fischer, Gustav E. Lienhard	70
18	Insulin and IGF‐I signaling through the insulin receptor substrate 1 1993 ·Molecular Reproduction and Development ·Susanne R. Keller, (unknown), Brian E. Lavan, Michelle Kuhne, Gustav E. Lienhard	17
19	The insulin receptor substrate 1 associates with the SH2-containing phosphotyrosine phosphatase Syp 1993 ·Journal of Biological Chemistry ·Michelle Kuhne, Tony Pawson, Gustav E. Lienhard, Guosheng Feng	342
20	The association of insulin-elicited phosphotyrosine proteins with src homology 2 domains. 1992 ·Journal of Biological Chemistry ·Brian E. Lavan, Michelle Kuhne, Charles W. Garner, Dirk Anderson, Michael Reedijk, Tony Pawson, Gustav E. Lienhard	94

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact